Viral Clearance Validation Study Protocol Inspection

Inspection template for documenting viral clearance validation studies across purification steps, including spiking study setup, orthogonal clearance methods, log-reduction value (LRV) calculations, and deviation handling in line with ICH Q5A(R2).

Study Scope and Protocol Control

• Protocol title, version, and effective date are documented
• Study objective clearly states viral clearance validation across defined purification steps
• Product, process, and manufacturing scale are identified
• Referenced governing documents include ICH Q5A(R2) and applicable internal SOPs
• Study roles and approvals are assigned to qualified personnel

Virus Panel and Spiking Strategy

• Virus panel includes relevant model viruses representing different physicochemical properties
• Virus stock identity, passage history, and titer are documented
• Spiking point and target spike ratio are defined for each challenged unit operation
• Spike recovery and hold-time controls are included where applicable
• Virus handling and containment controls are defined for the study

Purification Steps and Orthogonal Clearance Claims

• Each purification step evaluated for viral clearance is listed in process order
• Orthogonal clearance mechanisms are identified across steps
• Worst-case operating conditions are justified for each challenged step
• Process parameters affecting clearance are specified with acceptable ranges
• Inactivation and removal claims are not conflated in the protocol

Sampling, Assay Controls, and Analytical Method

• Pre- and post-step sample points are defined for each clearance unit operation
• Sample volumes, dilution scheme, and storage conditions are specified
• Assay method is qualified or validated for the intended matrix
• Assay controls include positive control, negative control, and matrix interference assessment
• Limit of detection and limit of quantitation are documented for the assay

Log-Reduction Calculations and Data Integrity

• LRV calculation method is defined for each step and for cumulative clearance
• Treatment of values below the assay detection limit is defined
• Replicate handling and averaging rules are specified
• Raw data, calculations, and audit trail are retained and traceable

Deviations, Acceptance Criteria, and Final Report

• Acceptance criteria for each clearance step and cumulative LRV are predefined
• Protocol deviations and out-of-trend results require documented assessment
• Final report includes conclusion on viral clearance adequacy and study limitations
• Final report is reviewed and approved by authorized quality and technical signatories